Clinical trials: System Sclerosis
Multiple Sclerosis
Intermittent Low Oxygen Breathing: A First Study Testing Different Disease Stages in People Living With MS
This study will look at the safety, tolerability and feasibility of a non-invasive treatment called Acute Intermittent Hypoxia (AIH) in people with Multiple Sclerosis (MS) at different stages of the disease course.
- Trial name
- LOxyMS (NCT07631143)
- Testing
- Acute Intermittent Hypoxia
- Volunteers
- 9 people
- Sponsor
- University of Saskatchewan
Rheumatoid Arthritis, Autoimmune Rheumatologic Disease
COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases
People living with Systemic autoimmune rheumatic diseases (SARDs) face a new and urgent dilemma: immunosuppression increases risk for worse COVID-19 infection, yet an immune stimulation, such as vaccination, could re-activate…
- Conditions
- Rheumatoid Arthritis, Autoimmune Rheumatologic Disease, Systemic Lupus Erythematosus, Systemic Vasculitis
- Trial name
- COVBIRD (NCT05236491)
- Testing
- COVID-19 vaccine
- Where
- 2 sites in Canada
- Volunteers
- 287 people
- Sponsor
- Paul R Fortin
ALS, ALS (Amyotrophic Lateral Sclerosis)
Systems Biology of Amyotrophic Lateral Sclerosis (ALS)
The goal of this observational study is to identify molecular features in multiple clinical samples and/or the patient environment that are associated with ALS.
- Trial name
- NCT07007390
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Viome
Amyotrophic Lateral Sclerosis, Home Mechanical Ventilation
Development in Home Mechanical Ventilation for Patient With Amyotrophic Lateral Sclerosis.
The aims of the study are to calculate the positive predictive value (PPV) of the codes for home mechanical noninvasive and invasive ventilation in patients with Amyotrophic lateral sclerosis in Denmark, and to describe the…
- Trial name
- NCT07819890
- Volunteers
- 400 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
MULTIPL SCLEROSİS
High-Intensity Interval Training for Walking and Function Across Different Multiple Sclerosis Disability Levels
Multiple Sclerosis (MS) is a chronic neurological disease that can affect daily functioning, mobility, and overall quality of life.
- Trial name
- NCT07771868
- Testing
- High-Intensity Interval Training
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Hacettepe University
Multiple Sclerosis
A Reeducation Program to Effort to Improve the Walking of Multiple Sclerosis Patients
Multiple sclerosis (MS) is a disease affecting the white matter of the central nervous system. In France, it concerns approximately 80 000 patients and represents one of the most frequent neurological affections in young adults.
- Trial name
- AEROSEP (NCT02874677)
- Testing
- Effort reeducation program
- Where
- 4 sites in France
- Volunteers
- 46 people
- Sponsor
- Lille Catholic University
Multiple Sclerosis
Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy
This study is to find out the safety and effectiveness of Avonex (interferon-beta-1a) Therapy in patients who have developed neutralizing antibodies during previous interferon-beta treatment
- Trial name
- SAFE (NCT00493077)
- Testing
- low immunogenic interferon-beta-1a
- Where
- 5 sites in Sweden
- Volunteers
- 3 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
Fingolimod -Response According to Coping - Evaluation
This is a prospective, open-label, multi-center phase IV study to assess response to fingolimod initiation according to coping profile in adult patients with highly active relapsing remitting multiple sclerosis in France.
- Trial name
- GRACE (NCT01420055)
- Testing
- fingolimod
- Where
- 47 sites in France
- Volunteers
- 189 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Remitting Multiple Sclerosis
Multiple Sclerosis Outcome Determination Evaluating Real Differences After TimE
To provide real world evidence evaluating whether a strategy of early initiation and escalation of disease modifying treatment (DMT) in relapsing-remitting multiple sclerosis (RRMS) affects disease outcome over a 10 year period.
- Trial name
- MODERATE (NCT05446285)
- Testing
- Clinical assessment
- Where
- United Kingdom
- Volunteers
- 245 people
- Sponsor
- NHS Greater Glasgow and Clyde
Traumatic Brain Injury, Stroke
Remote Neuropsychological Assessment of Patients With Neurological Disorders and Injuries
For the last decades, many aspects of human life have been altered by digital technology. For health care, this have opened a possibility for patients who have difficulties travelling a long distance to a hospital to meet with…
- Conditions
- Traumatic Brain Injury, Stroke, Multiple Sclerosis, Parkinson Disease
- Trial name
- NCT05819008
- Testing
- Neuropsychological Assessment
- Where
- Sweden
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Umeå University
Relapsing-remitting Multiple Sclerosis (RRMS)
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
The Main objectives of the study are to demonstrate pharmacokinetic (PK) similarity between ABP 692 and ocrelizumab (US), as well as between ABP 692 and ocrelizumab (EU).
- Trial name
- NCT06700343
- Testing
- Ocrelizumab (US), Ocrelizumab (EU), ABP 692
- Where
- 109 sites in United States, Belgium and 20 more
- Volunteers
- 152 people
- Sponsor
- Amgen
Multiple Sclerosis
Effects of Training on Central Auditory Function in Multiple Sclerosis
The purpose of this study is to characterize the central auditory processing (CAP) deficits that result from multiple sclerosis (MS).
- Trial name
- NCT01023074
- Testing
- Auditory training, MS: Control Activity
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Metformin Treatment in Progressive Multiple Sclerosis
The purpose of this study is to assess the safety of metformin for treatment of progressive multiple sclerosis
- Trial name
- NCT05349474
- Testing
- Metformin 500 Mg Oral Tablet, up to 4 tablets a day
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of California, Los Angeles
Pain, Multiple Sclerosis
Pain in Neurorehabilitation Through Wearable Devices: an Exploratory Study
This exploratory interventional study aims at exploring the feasibility of using physiological signals recorded through wearable devices, together with artificial intelligence techniques, to assess pain automatically and…
- Trial name
- PAINLESS (NCT05747040)
- Testing
- monitoring
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Azienda Usl di Bologna
Microstomia, Scleroderma
Hyaluronidase Via LADD Scleroderma-induced Microstomia
Two treatment methods, ablative carbon dioxide (CO2) laser and intradermal hyaluronidase, will be combined to maximize the beneficial potential of each.
- Trial name
- NCT05995626
- Testing
- Hyaluronidase, CO2 laser
- Where
- 2 sites in United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Multiple Sclerosis
Metacognition Assessment in Patient With Multiple Sclerosis
This study will assessed the level of consciousness of MS patients suffering of cognitive and motor disorders. Understanding the awareness of the disease is crucial to allow better management of these patients.
- Trial name
- METACOGSEP (NCT04240379)
- Where
- France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Grenoble
Relapsing Remitting Multiple Sclerosis
Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
The purpose of this study is to evaluate the safety and efficacy of NU100 in patients with relapsing remitting multiple sclerosis (RRMS) as compared to placebo and an active comparator.
- Trial name
- NCT01464905
- Testing
- NU100, rhIFN beta-1b
- Where
- 12 sites in Belarus, Bulgaria and 10 more
- Volunteers
- 500 people
- Sponsor
- Nuron Biotech Inc.
Scleroderma, Keloids
UVA1 Light for Treatment of Scleroderma and Similar Conditions
The purpose of this investigation is to evaluate the effectiveness of an investigational device which is similar in appearance to a "tanning bed" but which emits ultraviolet irradiation of a specific wavelength known as UVA1.
- Conditions
- Scleroderma, Keloids, Other Fibrosing Conditions
- Trial name
- NCT00476801
- Testing
- German manufactured UVA1 light emitting device
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Michigan
Amyotrophic Lateral Sclerosis (ALS)
Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III
The primary objective of this study is to evaluate the efficacy of 60mg of MCI-186 via intravenous drip once a day in patients with ALS whose severity is classified as grade III, based on the changes in the revised ALS functional…
- Trial name
- NCT00415519
- Testing
- MCI-186
- Volunteers
- 25 people
- Sponsor
- Shionogi
Amyotrophic Lateral Sclerosis
Ambulatory Versus Inpatient Initiation of Home Mechanical Ventilation
The purpose of this investigation is to see if outpatient initiation of noninvasive home mechanical ventilation combined with closed telemonitoring and follow-up in patients with amyotrophic lateral sclerosis is non-inferior to…
- Trial name
- NCT05829330
- Testing
- Outpatient, Hospitalization
- Where
- Denmark
- Volunteers
- 46 people
- Sponsor
- Anne Kathrine Staehr-Rye
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.